Palvella Therapeutics (PVLA) Stifel 2025 Healthcare Conference summary

Strategic focus and mission

• Aims to serve patients with serious rare skin diseases by developing and commercializing first FDA-approved therapies for conditions with no current treatments.

• Targets rare skin diseases with high unmet need and low competitive intensity, positioning to become a leader in this field.

• Focuses on diseases where over 98% lack approved therapies, leveraging a late-stage pipeline and strong capital base.

Pipeline and product development

• Lead product QTORIN rapamycin is a patented topical mTOR inhibitor, with multiple potential indications.

• Recently added angiocheratomas and disseminated superficial actinic porokeratosis (DSAP) as new indications.

• Ongoing clinical programs include phase II for cutaneous venous malformations (CVM) and phase III for microcystic lymphatic malformations (mLM).

• All programs use known APIs and pursue the 505(b)(2) regulatory pathway for expedited development.

• Plans to eventually expand into novel compounds as the platform matures.

Clinical progress and trial design

• Phase II for mLM showed 100% response rate, leading to breakthrough therapy and orphan drug designations.

• Phase III for mLM mimics phase II design, is fully enrolled with 51 patients, and will read out in Q1 2026.

• CVM phase II proof-of-concept study will read out in mid-December, with a 30% response rate considered a success threshold.

• Studies are single-arm, baseline-controlled, and designed in collaboration with key opinion leaders.